Drugs / rMenB + OMV NZ vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01339923 | Apr 2011 → Jan 2014 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rMenB + OMV NZ vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01339923 ↗ |
| Known as | 4CMenB | “This phase IIIb, open-label, multicentre, extension study (NCT01894919) evaluated long-term antibody persistence and booster responses in participants who received a reduced 2...” PMID 29253560 ↗ Dec 2017 |
| Modality | Vaccine | “meningococcal serogroup B (4CMenB) vaccine” PMID 31327652 ↗ Jul 2019 |